Send this to a friend

FDA approves Sunovion's lung disease drug

Sunovion Pharmaceutics of Marlborough has received U.S. Food and Drug Administration approval for a new drug treating COPD, or chronic obstructive pulmonary disease.
The drug, Lonhala Magnair, is expected to be available in pharmacies in early 2018, Sunovion announced Thursday.
Lonhala Magnair, an inhalation solution, is the first long-acting muscarinic antagonist to be approved for treating COPD, according to Su ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media